2. Search Result
Search Result
Results for "

centrally acting analgesic

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17001
    Flupirtine Maleate
    1 Publications Verification

    D 9998 Maleate

    		 Potassium Channel iGluR GABA Receptor Neurological Disease Inflammation/Immunology
    Flupirtine (D 9998) Maleate is an orally active, blood-brain barrier-crossing non-opioid analgesic and neuroprotective agent. Flupirtine Maleate is a neuronal potassium channel opener (Kv7 activator), a NMDA receptor antagonist and a GABA receptor activator. Flupirtine Maleate stabilizes blood-brain-barrier integrity, reduces oxidative stress and brain leukocyte infiltration, enhances angioneurogenesis, suppresses calcium influx, stabilizes neuronal resting membrane potential, and counteracts focal cerebral ischemia. Flupirtine Maleate exhibits analgesic, muscle relaxant properties, protects neurons from excitotoxic, ischemic, or cytokine-mediated death. Flupirtine Maleate functions as a non-opioid analgesic without antipyretic or antiphlogistic properties, shows no relevant affinity to opiate receptor. Flupirtine Maleate can be used for the research of focal cerebral ischemia, pain, Alzheimer’s disease, or multiple sclerosis .
    Flupirtine Maleate
  • HY-B1057
    Nefopam hydrochloride
    3 Publications Verification

    Fenazoxine hydrochloride

    		 β-catenin Neurological Disease Cancer
    Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    Nefopam hydrochloride
  • HY-B1288A
    Oxybuprocaine

    Benoxinate; Novesinol; Oxybucaine

    		 Sodium Channel Cardiovascular Disease Neurological Disease
    Oxybuprocaine is a short-acting ester anesthetic. Oxybuprocaine binds to sodium channels and reversibly stabilizes neuronal membranes. Oxybuprocaine has cutaneous analgesic properties. Oxybuprocaine is less potent than Bupivacaine (HY-B0405) at producing central nervous system and cardiovascular toxicity. Oxybuprocaine can be used in ophthalmology and otolaryngology .
    Oxybuprocaine
  • HY-121644
    Viminol

    		Opioid Receptor Neurological Disease
    Viminol is a centrally acting analgesic agent. Viminol also shows antitussive activity .
    Viminol
  • HY-B1057S1
    Nefopam-d4 hydrochloride

    Fenazoxine-d4 hydrochloride

    		 Isotope-Labeled Compounds β-catenin Neurological Disease
    Nefopam-d4 (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    Nefopam-d4 hydrochloride
  • HY-133195
    Nefopam

    Fenazoxine

    		 Sodium Channel Neurological Disease
    Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 μM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups .
    Nefopam
  • HY-B1057S2
    Nefopam-d3

    Fenazoxine-d3

    		 β-catenin Neurological Disease
    Nefopam-d3 is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells .
    Nefopam-d3
  • HY-100294
    Ruzadolane

    UP 26-91

    		 Others Neurological Disease
    Ruzadolane (UP 26-91) is a non-narcotic, centrally-acting analgesic agent.
    Ruzadolane
  • HY-133115AS
    N-Desmethylnefopam-d5 hydrochloride

    		Isotope-Labeled Compounds β-catenin Neurological Disease
    N-Desmethylnefopam-d5 (hydrochloride) is a deuterium labeled N-Desmethylnefopam hydrochloride. N-Desmethylnefopam hydrochloride is the main metabolite of Nefopam. N-Desmethylnefopam hydrochloride is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain .
    N-Desmethylnefopam-d5 hydrochloride
  • HY-17001R
    Flupirtine Maleate (Standard)

    D 9998 Maleate (Standard)

    		 Reference Standards Potassium Channel iGluR GABA Receptor Neurological Disease Inflammation/Immunology
    Flupirtine Maleate (Standard) is the analytical standard of Flupirtine Maleate (HY-17001). This product is intended for research and analytical applications. Flupirtine Maleate is an orally active, blood-brain barrier-crossing non-opioid analgesic and neuroprotective agent. Flupirtine Maleate is a neuronal potassium channel opener (Kv7 activator), a NMDA receptor antagonist and a GABA receptor activator. Flupirtine Maleate stabilizes blood-brain-barrier integrity, reduces oxidative stress and brain leukocyte infiltration, enhances angioneurogenesis, suppresses calcium influx, stabilizes neuronal resting membrane potential, and counteracts focal cerebral ischemia. Flupirtine Maleate exhibits analgesic, muscle relaxant properties, protects neurons from excitotoxic, ischemic, or cytokine-mediated death. Flupirtine Maleate functions as a non-opioid analgesic without antipyretic or antiphlogistic properties, shows no relevant affinity to opiate receptor. Flupirtine Maleate can be used for the research of focal cerebral ischemia, pain, Alzheimer’s disease, or multiple sclerosis .
    Flupirtine Maleate (Standard)
  • HY-133115
    N-Desmethylnefopam

    		β-catenin Neurological Disease
    N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    N-Desmethylnefopam
  • HY-B1057S
    Nefopam-d3 hydrochloride

    Fenazoxine-d3 hydrochloride

    		 β-catenin Neurological Disease
    Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    Nefopam-d3 hydrochloride
  • HY-W015618R
    2',4'-Dimethylacetophenone (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Nefopam (hydrochloride) (Standard) is the analytical standard of Nefopam (hydrochloride). This product is intended for research and analytical applications. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    2',4'-Dimethylacetophenone (Standard)
  • HY-B1057R
    Nefopam hydrochloride (Standard)

    Fenazoxine hydrochloride (Standard)

    		 Reference Standards β-catenin Neurological Disease Cancer
    Nefopam (hydrochloride) (Standard) is the analytical standard of Nefopam (hydrochloride). This product is intended for research and analytical applications. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    Nefopam hydrochloride (Standard)
  • HY-133115S
    N-Desmethylnefopam-d5

    		Isotope-Labeled Compounds β-catenin Neurological Disease
    N-Desmethylnefopam-d5 is the deuterium labeled N-Desmethylnefopam (HY-133115). N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
    N-Desmethylnefopam-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: